Novo Nordisk AS announced the latest research results on semaglutide: higher doses of Wegovy can lead to an average weight loss of 21% for patients with obesity

智通財經
2025.06.21 03:49
6 月 21 日，據諾和諾德網站消息，在芝加哥舉行的美國糖尿病協會科學會議上，諾和諾德公佈了針對非糖尿病肥胖症患者的 3b 期 STEPUP 試驗結果。數據顯示，在 72 周治療期內，與安慰劑相比，更高劑量 Wegovy®可使肥胖症患者平均減重 21%，其中三分之一受試者減重幅度達 25% 或更高。更高劑量 Wegovy 的安全性和耐受性與 2.4mg 劑量一致。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.